NATICK, Mass., July 24, 2013 /PRNewswire/ -- The Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance, CE Mark and Japan PMDA approval for its OptiCross™ Coronary Imaging Catheter and has launched the device in the U.S. and Europe. A launch in Japan is planned for later this month. OptiCross, a next generation intravascular ultrasound (IVUS) catheter, offers better deliverability and higher resolution imaging to facilitate complex coronary procedures.
Designed to be compatible with the Boston Scientific iLab® Ultrasound Imaging System, the OptiCross catheter was created with the input of physicians from around the world to reduce the inherent challenges surrounding catheter delivery in complex cases. The upgraded, low profile delivery system features 5 French guide catheter compatibility, a shorter, tapered tip, a bi-segmented catheter shaft and a redesigned catheter hub for ease of connection.
"The OptiCross catheter was designed for optimal deliverability and its performance proves it," said Matthew Price, M.D., interventional cardiologist and director of the Cardiac Catheterization Laboratory, Scripps Green Hospital, San Diego. "Now I can use IVUS technology in complex cases where I would not have been able to deliver an IVUS catheter before."
Interventional cardiologists use IVUS to see inside coronary arteries and to gain additional information in order to optimize treatment decisions."The OptiCross catheter widens the applicability of ultrasound with the ability to assess disease pre-procedure, without concern regarding ischemia and lesion trauma," said Dr. Neal Uren, clinical director for cardiac services at the Edinburgh Heart Centre, Royal Infirmary, Edinburgh. "The incremental increase in deliverability widens the use of IVUS into more difficult lesion subsets, while maintaining superior image quality." The benefits of IVUS-guided percutaneous coronary intervention (PCI) were reinforced at TCT 2012 and at EuroPCR in May with the presentation of the ADAPT-DES IVUS sub-study outcomes. The results showed that IVUS can help improve patient outcomes and change the way physicians approach their cases.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV